Advertisement

Breast Cancer Research and Treatment

, Volume 65, Issue 2, pp 135–144 | Cite as

Change in Expression of ER, bcl-2 and MIB1 on Primary Tamoxifen and Relation to Response in ER Positive Breast Cancer

  • Frances S. Kenny
  • Peter C. Willsher
  • Julia M.W. Gee
  • Robert I. Nicholson
  • Sarah E. Pinder
  • Ian O. Ellis
  • John F.R. Robertson
Conference Report

Abstract

Pre-treatment oestrogen receptor (ER) expression in breast cancer predicts for rate of response to endocrine therapy but not for the quality or duration of response (DofR). ER is known to be down-regulated by anti-oestrogens. This study has tested the hypothesis that the degree of down-regulation of ER and the ER-regulated marker bcl-2 are associated with the quality and duration of tamoxifen response. 80 patients with ER+ve breast cancer (H-score ≥10) receiving primary tamoxifen (n=51 Stage I–II elderl; n=29 Stage III) underwent sequential tumour biopsies for immunocytochemical assessment of ER, bcl-2 and the proliferation marker MIB1. Median follow-up is 45 months. By 6-months on therapy three patients had attained complete response (CR), 27 partial response (PR); 44 static disease (SD) and six progression (PD) by UICC criteria. Greater decrease in ER and bcl-2 H-score from pre-treatment to 6 weeks (p=0.035, p=0.037) and ER and bcl-2 H-score from pre-treatment to 6 months (p=0.058, p=0.036) were significantly associated with better quality of response (CR/PR vs SD/PD). Greater 6-week and 6-month reduction in bcl-2 H-score (p=0.041, p=0.036) and 6-week reduction in MIB1 (p=0.013) were significantly correlated with longer DofR. This study demonstrates that greater down-regulation of ER and the ER-regulated protein bcl-2 on primary tamoxifen are significantly associated with a better quality of response and bcl-2 and the proliferation marker MIB1 a longer duration of response in ER+ve breast cancer.

ER bcl-2 MIB1 primary tamoxifen endocrine response 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Robertson JFR, Cannon PM, Nicholson RI, Blamey RW: Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer. Int J Biol Markers 11(1): 29-35, 1996Google Scholar
  2. 2.
    Ravdin PM, Green S, Melink Dorr T, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10(8): 1284-1291, 1992Google Scholar
  3. 3.
    Hayward JL, Carbone PP, Henson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to treatment in advanced breast cancer. Cancer 39: 1289-1293, 1977Google Scholar
  4. 4.
    British Breast Group: Assessment of response to treatment in advanced breast cancer. Lancet 2: 38-9, 1974Google Scholar
  5. 5.
    Robertson JFR, Ellis IO, Nicholson RI, Robins A, Bell J, Blamey RW: Cellular effects of primary tamoxifen in breast cancer. Breast Cancer Res Treat 20: 117-123, 1991Google Scholar
  6. 6.
    Willsher PC: Biological changes in primary breast cancer during systemic therapy. D.M. Thesis, Nottingham University, 1996Google Scholar
  7. 7.
    Robertson JFR: Oestrogen receptor: a stable phenotype in breast cancer. B J Cancer 73: 5-12, 1996Google Scholar
  8. 8.
    Coombes RC, Powles TJ, Berger V, Wilson P, McClelland RA, Gazet JC, Trott PA, Ford HT: Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirate. Lancet 2: 701-703, 1987Google Scholar
  9. 9.
    Johnston SRD, Haynes BP, Smith IE, Jarman M, Sacks NPM, Dowsett M: Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 2: 1521-1522, 1994Google Scholar
  10. 10.
    DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JFR, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling A: Investigation of a new pure anti-oestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 54: 408-414, 1994Google Scholar
  11. 11.
    McClelland RA, Gee JMW, Francis AB, Robertson JFR, Blamey RW, Wakeling AE, Nicholson RI: Short-term effects of pure anti-oestrogen ICI 1827 80 treatment on oestrogen receptor, epidermal growth factor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 3: 413-416, 1996Google Scholar
  12. 12.
    Robertson JFR, Nicholson RI, Anderson E, Dowsett M, Ellis IO, Dixon JM, Bundred N, Webster A, Morris C: The anti-tumor effects of single dose, long acting Faslodex (ICI 182,780) compared with Tamoxifen in post-menopausal primary breast surgery patients treated before surgery (Abstract). Breast Cancer Res Treat 57: 31 (28), 1999Google Scholar
  13. 13.
    Howell A, De Friend DJ, Robertson JFR, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 1827 80 in women with advanced breast cancer. Br J Cancer 74: 300-308, 1996Google Scholar
  14. 14.
    Robertson JFR, Howell A, De Friend DJ, Blamey RW, Walton P: Duration of remission to ICI 182, 780 compared to megestrol acetate in tamoxifen resistant breast cancer. Breast 6: 186-189, 1997Google Scholar
  15. 15.
    Gee JMW, Robertson JFR, Ellis IO, Willsher PC, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994Google Scholar
  16. 16.
    Soubeyran I, Quenel N, Coindre J-M, Bonichon F, Durand M, Wafflart J, Mauriac L: pS2 protein: amarker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 74: 1120-1125, 1996Google Scholar
  17. 17.
    Kenny FS, Pinder S, Ellis IO, Gee JMW, Nicholson RI, Bryce RP, Robertson JFR: Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer 85: 643-648, 2000Google Scholar
  18. 18.
    Goulding H, Pinder S, Cannon P, Pearson D, Nicholson RI, Robertson JF, Blamey RW, Ellis IO: A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Human Path 26(3): 291-294, 1995Google Scholar
  19. 19.
    Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, Mc-Carty KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 49: 1052-1056, 1989Google Scholar
  20. 20.
    Snead DRJ, Bell JA, Dixon AR, Nicholson RI, Elston CW, Blamey RW, Ellis IO: Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 23: 233-238, 1993Google Scholar
  21. 21.
    Cattoretti G, Becker MH, Key G, Duchrow M, Schlter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating in micro-wave processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992Google Scholar
  22. 22.
    Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13(2): 513-529, 1995Google Scholar
  23. 23.
    Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Coicca D, Ravdin P, O'sullivan J, Rivkin S, Martino S, Osbourne KC: Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 15(5): 1916-1922, 1997Google Scholar
  24. 24.
    Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606-611, 1993Google Scholar
  25. 25.
    Johnston SRD, MacLennon KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30(11): 1663-1669, 1994Google Scholar
  26. 26.
    Watts CKW, Sweeney KJE, Warlters A, Musgrove EA, Sutherland RL: Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 31: 95-105, 1994Google Scholar
  27. 27.
    Nicholson RI, Bouzubar N, Walker KJ, McClelland RA, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 27(7): 908-913, 1991Google Scholar
  28. 28.
    Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC, Dowsett M: Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 48: 11-20, 1998Google Scholar
  29. 29.
    Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C, Miller RW: The expression of Ki-S1 and bcl-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat 44: 123-133, 1997Google Scholar
  30. 30.
    Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in oestrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995Google Scholar
  31. 31.
    Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994Google Scholar
  32. 32.
    Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptornegative tumours and in situ cancer. Breast J Cancer 69: 135-139, 1994Google Scholar
  33. 33.
    Bhargava V, Kell DL, Van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Path 145(3): 535-540, 1994Google Scholar
  34. 34.
    Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995Google Scholar
  35. 35.
    Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K: Apoptosis suppressing prote in bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177(1): 49-55, 1995Google Scholar
  36. 36.
    Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 prote in expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Annals Oncol 6: 1005-1010, 1995Google Scholar
  37. 37.
    Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T, Masaoka A: Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 42: 173-181, 1997Google Scholar
  38. 38.
    Castle VP, Heidelburger KP, Bromberg, J, Ou X, Dole M, Nunez G: Expression of the apoptosis-suppressing prote in bcl-2 in neuroblastoma is associated with unfavorable histology and n-myc amplification. Am J Pathol 143: 1543-1550, 1993Google Scholar
  39. 39.
    McDonnell TJ, Toncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992Google Scholar
  40. 40.
    Bronner MP, Culin C, Reed JC, Futh EE: The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146: 20-26, 1995Google Scholar
  41. 41.
    Perry R, Kang Y, Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent human breast cancer cells. Ann Surg Oncol 2: 238-347, 1995Google Scholar
  42. 42.
    Dowsett M, Johnston SRD, Newby J, Golding M, Sacks A, Smith IE. Mechanisms of hormone response: a role for apoptosis. Endocrine-related Cancer 2(1): 3-11, 1995Google Scholar
  43. 43.
    Dowsett M, Johnston SRD, Detre S, Salter J, Humphries S, Saccani-Jotti G, Smith IE, MacLennan K, Trott P: Cytological evaluation of biological variables in breast cancer patients undergoing primary medical treatment. In: Motta M, Serio M (eds) Sex Hormones and Anti-hormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Elsevier Science Publishers, Amsterdam, 1994, pp 329-336Google Scholar
  44. 44.
    Namer M, Lalanne C, Baulieu E-E: Increase of progesterone receptor by tamoxifen as a hormonal challenge in breast cancer. Cancer Res 40: 1750-1752, 1980Google Scholar
  45. 45.
    Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Haywood E, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300-304, 1987Google Scholar
  46. 46.
    Noguchi S, Miyauchi K, Nishizawa Y, Koyama H: Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behaviour over time. Cancer 61: 1345-1349, 1988Google Scholar
  47. 47.
    Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M, Klijn JGM: Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223, 1994Google Scholar
  48. 48.
    Nicholson RI, Gee JMW, Eaton CL, Manning DL, Mansel RE, Sharma AK, Douglas-Jones A, Price-Thomas M, Howell A, DeFriend D. J, Bundred NJ, Anderson E, Robertson JFR, Blamey RW, Dowsett M, Baum M, Walton P, Wakeling AE: Pure anti-estrogens in breast cancer: experimental and clinical observations. In: Motta M, Serio M (eds) Sex Hormones and Anti-hormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Elsevier Science Publishers, Amsterdam, 1994, pp. 347-360Google Scholar
  49. 49.
    McClelland RA, Manning DL, Gee JMW, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JFR, Blamey RW, Wakeling AE, Nicholson RI: Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and prote in expression and on estrogenregulated genes. Breast Cancer Res Treat 41: 31-41, 1996Google Scholar
  50. 50.
    Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Frances S. Kenny
    • 1
  • Peter C. Willsher
    • 1
  • Julia M.W. Gee
    • 2
  • Robert I. Nicholson
    • 2
  • Sarah E. Pinder
    • 3
  • Ian O. Ellis
    • 3
  • John F.R. Robertson
    • 1
  1. 1.Professorial Unit of SurgeryNottingham City HospitalNottinghamUK
  2. 2.Tenovus Cancer Research CentreUniversity of Wales College of MedicineCardiffUK
  3. 3.Department of HistopathologyNottingham City HospitalNottinghamUK

Personalised recommendations